Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Pfizer    PFE

Mes dernières consult.
Most popular
Delayed Quote. Delayed  - 02/16 10:01:18 pm
36.26 USD   +1.54%
02/16DOW MOVERS : Mcd, csco
02/16PFIZER : Receives Breakthrough Therapy Designation from FDA for PF-0..
02/16PFIZER : FDA investigating misuse, abuse of gabapentinoids
News SummaryMost relevantAll newsSector newsTweets

Pfizer : Sells Its 49% Equity Share in Hisun-Pfizer Pharmaceuticals

share with twitter share with LinkedIn share with facebook
share via e-mail
11/10/2017 | 05:59pm CET

Pfizer Inc. (NYSE: PFE) and Zhejiang Hisun Pharmaceuticals (Hisun) today announced that Pfizer has sold its 49% equity share in its joint venture, Hisun-Pfizer Pharmaceuticals Co., Ltd. to Sapphire I (HK) Holdings Limited. Hisun-Pfizer Pharmaceuticals Co., Ltd. is a joint venture formed by Pfizer and Hisun in 2012 to develop, manufacture and commercialize branded generic pharmaceutical products in China and global markets. The transfer of Pfizer's equity stake will allow both Hisun and Pfizer to focus on their core strengths. After Pfizer's equity share transfer, the joint venture will change its name but will retain its current rights to manufacture, sell and distribute all of Hisun-Pfizer Pharmaceutical's currently marketed and pipeline products in China.

The joint venture will benefit from Pfizer's world class international manufacturing expertise as Pfizer will provide technical, manufacturing and regulatory support services.
Pfizer will continue to support a technology transfer process to ensure that the products that had previously been licensed to Hisun-Pfizer Pharmaceuticals by Pfizer, will in the future, be manufactured locally in China. Pfizer will continue to supply certain products to the joint venture for a period of time, after closing, to facilitate a smooth transition.

Pfizer and Hisun will maintain a strong and collaborative relationship, providing for the ongoing supply of high-quality generic products to patients in China through the joint venture.

PFIZER DISCLOSURE NOTICE: The information contained in this release is as of 10 November 2017. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information related to, among other things, an agreement between a Pfizer affiliate and Sapphire I (HK) Holdings Ltd pursuant to which, such Pfizer affiliate has sold its equity share in Hisun-Pfizer Pharmaceuticals Co., Ltd to Sapphire I (HK) Holdings Limited, including the potential benefits of the transaction and the anticipated ongoing and future relationship between Pfizer and the joint venture, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, risks related to the ability to realize the anticipated benefits of the transaction; risks related to potential disruption from the transaction; and other business effects, including the effects of industry, market, economic, political or regulatory conditions or unknown liabilities or costs.
A further description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2016 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results", as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov(link is external)and www.pfizer.com.

About Zhejiang Hisun Pharmaceuticals
Founded in 1956, the mission for Zhejiang HISUN Pharmaceuticals Co., Ltd. (stock code 600267) hereinafter called "HISUN" is to be persistent in pharmaceutical innovation for human well-being. The company's vision is to become a widely respected global pharmaceutical provider. It focuses on the integration of pharmaceutical research and development (R&D) with production resources in order to provide its global customers with outstanding products and services. To date, over 40 of the company's products have passed certification by the FDA (U.S.), EDQM (EU), TGA (Australia), KFDA(Korea), etc., and are sold to more than 30 countries worldwide. To learn more about Hisun, please visit http://www.hisunpharm.com/(link is external).

Pfizer Inc.: Working together for a healthier world™
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.pfizer.com. In addition, to learn more, please visit us on www.pfizer.com and follow us on Twitter at @Pfizer and @Pfizer_News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.


Media Contacts:
Steve Danehy
(212) 733-1538
[email protected](link sends e-mail)

Trupti Wagh
+65 9187 3247
[email protected](link sends e-mail)

Loucineh Mardirossian
+61 472812771
[email protected]

Pfizer Inc. published this content on 10 November 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 10 November 2017 16:58:03 UTC.

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on PFIZER
02/17PFIZER : Avelumab Falls Short in Phase III NSCLC Trial
02/17Merck/Pfizers cancer immunotherapy latecomer hits a snag
02/16DOW MOVERS : Mcd, csco
02/16PFIZER : Receives Breakthrough Therapy Designation from FDA for PF-04965842 an o..
02/16PFIZER : FDA investigating misuse, abuse of gabapentinoids
02/16PFIZER : Merck and Pfizer Provide Update on Phase III JAVELIN Lung 200 Trial of ..
02/16PFIZER : T Mobile Us (TMUS) Holder Swarthmore Group Increased Its Stake by $311,..
02/16PFIZER : J&J gets quick approval for new next-gen prostate cancer drug
02/15PFIZER : Reports from Pfizer Describe Recent Advances in Amyloid [Identification..
02/15AbbVie to buy back $10 billion of shares, raises dividend
More news
News from SeekingAlpha
02/173 THINGS IN BIOTECH YOU SHOULD LEARN : February 17, 2018 
02/16Celgene's Otezla-Colitis Story; Implications For Other Biotechs 
02/16BRUTE FORCE : Bring On The Machines 
02/16Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q4 2017 Update 
02/13YOUR DAILY PHARMA SCOOP : A Look At Celldex, BeiGene Data, Axovant Announces Cha.. 
Financials ($)
Sales 2018 54 410 M
EBIT 2018 20 806 M
Net income 2018 13 101 M
Debt 2018 22 213 M
Yield 2018 3,85%
P/E ratio 2018 16,28
P/E ratio 2019 15,15
EV / Sales 2018 4,32x
EV / Sales 2019 4,18x
Capitalization 213 B
Duration : Period :
Pfizer Technical Analysis Chart | PFE | US7170811035 | 4-Traders
Technical analysis trends PFIZER
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 40,3 $
Spread / Average Target 13%
EPS Revisions
Ian C. Read Chairman & Chief Executive Officer
Albert Bourla Chief Operating Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
Mikael Dolsten President-Worldwide Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER-2.84%212 857
JOHNSON & JOHNSON-7.19%352 552
NOVARTIS-3.37%224 301
ROCHE HOLDING LTD.-9.37%210 327
MERCK AND COMPANY-0.50%149 572
AMGEN3.23%133 277